Marinomed has already achieved many milestones in its short history. The selected scientific publications and press releases provide information on the most important events to date.
May 19, 2022
Marinomed Biotech AG enters into license agreement with Procter & Gamble on Carragelose® products
May 17, 2022
Marinomed to attend several upcoming investor conferences
April 28, 2022
Marinomed’s Australian Carragelose distribution network strengthened
April 13, 2022
Marinomed reports on strong 2021 financial year
April 12, 2022
Marinomed Biotech AG signs new agreement for Carragelose in South Korea
February 15, 2022
Marinomed receives € 6 m with final tranche of financing agreement with EIB to invest in proprietary R&D pipeline
January 27, 2022
Marinomed announces preliminary revenues for 2021, highest in its history
January 21, 2022
Marinomed announces the appointment of Dr. Cornelia Kutzer as Chief Business Officer
December 09, 2021
Marinomed and Friedrich-Alexander-Universität Erlangen-Nürnberg publish new data on antiviral efficacy of iota-carrageenan against SARS-CoV-2 variants of concern
December 01, 2021
Marinomed to present at Munich capital market conference (MKK)
November 22, 2021
Marinomed Biotech AG Reports Significant Revenue Growth for the First 9 Months 2021
November 03, 2021
Solv4U: Marinomed launches new business area enabling the development of innovative formulations in technology partnerships
October 28, 2021
Marinomed updates financial calendar and participates in upcoming industry and investor conferences
October 27, 2021
Marinomed partners with Perrigo to distribute virus-blocking Carragelose nasal spray in Scandinavia and France
October 20, 2021
First Marinosolv® platform deal: Marinomed Biotech AG and Luoxin Pharmaceutical Group Stock Co., Ltd. sign agreement on Budesolv to treat allergic rhinitis in Greater China
October 05, 2021
Marinomed Biotech AG signs financing agreement with Nice & Green S.A. to advance its scientific and clinical programs
October 04, 2021
Marinomed Biotech AG signs financing agreement with Nice & Green S.A. to advance its scientific and clinical programs
September 23, 2021
Marinomed’s Investor Relations to be Strengthened by Stephanie Kniep
September 09, 2021
Marinomed Biotech AG publishes clinical data on efficacy of Carragelose lozenges against respiratory viruses including SARS-CoV-2 in the International Journal of General Medicine
August 25, 2021
Marinomed Biotech AG Reports Financial Results for 1st Half 2021 with significant revenue growth
July 15, 2021
Marinomed Biotech AG announces grant of Chinese Patent covering the proprietary Marinosolv technology to generate aqueous solutions from insoluble compounds
July 06, 2021
Marinomed Biotech AG expands distribution of Corona virus blocker Carragelose into Brazil and Mexico
July 01, 2021
Marinomed Biotech AG Reports Encouraging Topline Data for Phase II Clinical Trial of Tacrosolv in Allergic Rhinoconjunctivitis
May 26, 2021
Marinomed Biotech AG Reports Financial Results for 1st Quarter 2021: Growth in Sales, due to persistent strong demand in Carragelose-based virus blockers
April 21, 2021
Marinomed Biotech AG announces positive data demonstrating Carragelose efficacy against SARS-CoV-2 variants
April 14, 2021
Marinomed Biotech AG Reports Financial Results for Fiscal Year 2020 and Record Sales For Virus Blocker Carragelose
April 12, 2021
Last Patient Completes Marinomed Biotech AG’s Phase II Clinical Trial of Tacrosolv to Treat Ocular Hay Fever Symptoms
March 24, 2021
Marinomed Biotech AG enrolls first patient in clinical study of inhaled Carragelose to treat COVID-19 infections
March 11, 2021
Marinomed Biotech AG Enrolls First Patients in Phase II Clinical Trial of Tacrosolv to Treat Allergic Rhinoconjunctivitis (Hay Fever)
February 26, 2021
Marinomed Biotech AG Leads BCG’s Gender Diversity Index Austria 2020
February 24, 2021
Marinomed Biotech AG announces positive clinical data for Carragelose lozenges against respiratory viruses including SARS-CoV-2
February 19, 2021
Marinomed Biotech AG shares positive clinical trial results for iota-carrageenan nasal spray in the prevention of COVID-19
February 19, 2021
Marinomed Biotech AG shares positive clinical trial results for iota-carrageenan nasal spray in the prevention of COVID-19
February 18, 2021
Marinomed Biotech AG publishes new supporting data on the in vitro efficacy of Carragelose® against SARS-CoV-2
January 29, 2021
Marinomed Biotech AG announces preliminary revenues and confirms outlook for 2020
December 16, 2020
Marinomed Biotech AG announces grant of European Patent covering the proprietary Marinosolv® technology to generate aqueous solutions from insoluble compounds
November 29, 2020
Marinomed Biotech AG announces clinical trial at Swansea University Medical School to investigate efficacy of Carragelose in preventing COVID-19 infections
November 26, 2020
Marinomed Biotech reports record sales in the first nine months of 2020 and a positive outlook
November 20, 2020
Marinomed Biotech plans clinical trial with Carragelose nasal spray to investigate prevention of COVID-19 infection in frontline healthcare staff
October 30, 2020
Marinomed Biotech AG announces change to supervisory board
October 08, 2020
Marinomed Biotech AG develops first medicinal product for the treatment of autoimmune gastritis
September 08, 2020
Marinomed applies for drug approval for new decongestant nasal spray in Europe
August 27, 2020
Marinomed with record sales in H1 2020 - high growth opportunities with virus blocker in the fight against coronavirus
July 16, 2020
Marinomed Biotech AG: Carragelose® effective against SARS-CoV-2 in cell culture assays
June 02, 2020
Marinomed expands into Italy and broadens its portfolio
May 26, 2020
Marinomed with significant sales increase in Q1 2020
May 14, 2020
Marinomed: Postponement of the Annual General Meeting to September 17, 2020
April 28, 2020
Marinomed receives FFG funding to research SARS-CoV-2 therapy based on Carragelose®
April 16, 2020
Marinomed with record sales in 2019 and positive outlook for 2020
March 09, 2020
Marinomed Biotech AG extends the range of Marinosolv® applications
February 06, 2020
Marinosolv® technology successfully used in preclinical study in severe eye disease Neurotrophic keratopathy
January 22, 2020
Marinomed Biotech AG: Sellers complete accelerated bookbuilding; 105,000 Marinomed shares have been sold for EUR 95 per share
January 22, 2020
Marinomed Biotech AG: Shareholders offer shares by way of an accelerated bookbuilding
November 29, 2019
Marinomed paves the way for long term growth in Q1 3/2019
November 26, 2019
Marinomed Biotech AG: Detailed clinical data show rapid onset of action of Budesolv to alleviate hay fever
October 16, 2019
Marinomed Biotech AG: aws Mittelstandsfonds and Invest AG sold Marinomed shares by way of an accelerated bookbuilding for EUR 95 per share to institutional investors
October 15, 2019
Marinomed Biotech AG: aws Mittelstandsfonds and Invest AG start partial sale of Marinomed shares by way of an accelerated bookbuilding
August 30, 2019
Marinomed: Investments in strong technology portfolio in first half-year 2019
May 29, 2019
Marinomed: Focus on future investments in Q1 2019
May 15, 2019
Marinomed Biotech AG: Budesolv with a strongly decreased dose of the active ingredient compared to the marketed product Rhinocort Aqua shows pronounced efficacy already after first application – clinical validation of the Marinosolv® platform
April 30, 2019
In 2018, Marinomed set the course for accelerated growth
April 23, 2019
Marinomed Biotech AG announces top line results of the Phase III study for Budesolv
February 28, 2019
Marinomed Biotech AG: Greenshoe option fully exercised
February 26, 2019
Marinomed receives EUR 15m EIB financing
February 18, 2019
Marinomed announces result of conversion of convertible bonds
January 29, 2019
Marinomed sets offer price at 75 Euro per share
January 29, 2019
Marinomed announces strong investor demand and expected offer price
January 23, 2019
Marinomed resumes offer period of the IPO
December 21, 2018
Screening of pivotal clinical trial completed
November 29, 2018
Marinomed suspends offer period of the current IPO
November 28, 2018
Viennese biotech company Marinomed demonstrates the benefits of its patented Marinosolv® technology
November 16, 2018
Marinomed determines IPO timeline and terms
November 05, 2018
Marinomed intends to conduct an IPO on the Vienna Stock Exchange
October 19, 2018
Initiation of Phase III clinical trial
August 29, 2018
Vienna-based biotech company Marinomed on a growth path
August 07, 2018
Vienna-based Biotech Company Marinomed obtains EU-wide Certification for new cold Medication
July 31, 2018
Pascal Schmidt appointed CFO as Vienna based biotech firm Marinomed strengthens its management team – Company reports strong growth.
November 27, 2017